CF PharmTech, Inc.
↗Suzhou, China
CF PharmTech is a specialty pharmaceutical company focused on the research, development, manufacturing, and commercialization of inhalation technologies and respiratory drugs. The company specializes in treatments for asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis.
Headquartered in Suzhou, China, the company operates as an integrated CDMO and innovator, developing formulations and delivery devices such as metered-dose inhalers (MDI), dry powder inhalers (DPI), and nasal sprays. It transitioned to a public company following its listing on the Hong Kong Stock Exchange (SEHK) in October 2025.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$100M-$500M
Founded:2007
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$206M
Investors:New Alliance Capital, BioTrack Capital, CICC Capital, SDIC Innovation, Passion Capital, Yuanming Capital
STOCK
Exchange:SEHK
Ticker:2652
Market Cap:HK$6.08B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, RNAi
Active Trials:21
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:CF PharmTech Hongkong Limited
COMPETITION
Position:Niche Player
Competitors:Jazz Pharmaceuticals, Sana Biotechnology, C4 Therapeutics
LEADERSHIP
Key Executives:
LIANG Wen Qing - CEO, General Manager, Chairman
ZHU Yu Yu - Vice General Manager, Board Secretary
WEI Wei - CFO
LINKS
Website:cfpharmtech.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of CF PharmTech, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with CF PharmTech, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.